Showing 831-840 of 8196 results for "".
Galderma's Differin Goes OTC, CoolSculpting Approved for Upper Arms, ZO Skin Acquires ReFissa
https://practicaldermatology.com/series/dermwire-tv/galderma-s-differin-goes-otc-coolsculpting-approved-for-upper-arms-zo-skin-acquires-refissa/18549/Galderma's Differin Gel formulation of adapalene 0.1% is now available over the counter at major retail and drug stores in the US. ZELTIQ® Aesthetics' CoolSculpting is now FDA-cleared for fat reduction in the upper arms. ZO Skin Health has acquired the worldwide rights to ReFissa from Suneva MedicalLaser hair removal in darker skin types, challenges and technological advances for treatment
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-hair-removal-in-darker-skin-types-challenges-and-technological-advances-for-treatment/18800/Andrew Alexis, MD discusses laser hair removal treatment challenges in patients with higher Fitzpatrick skin types, and how recent advances in technology have been able to address these to deliver effective treatment with minimal pain.ASDS: Dr. Farah on Hair Loss Treatment Options
https://practicaldermatology.com/conferences/asds-2024-annual-meeting/asds-dr-farah-hair-regrowth-options/29152/Ronda Farah, MD, discusses treatment options for hair loss, including platelet-rich plasma and lasers, at the 2024 American Society for Dermatologic Surgery Annual Meeting.Journal Club: New Research in Atopic Dermatitis
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-new-research-in-atopic-dermatitis/26560/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, chats with dermatologist Larry Eichenfield, MD, a member of the Practical Dermatology Editorial Board, about new research in atopic dermatitis (AD), as well as practical considerations and new treatments for the condition.Differentiating GPP From Plaque Psoriasis for Targeted Therapy
https://practicaldermatology.com/issues/august-2025/differentiating-gpp-from-plaque-psoriasis-for-targeted-therapy/36700/While all types of psoriasis carry significant burdens of disease for patients, certain subtypes have more severe symptoms and require more urgency in diagnosis and treatment. Generalized pustular psoriasis (GPP) is one such subtype and may be considered a disease entity with a classification of itsSCALE 2024: Listen as Dr. Joel Cohen Interviews Dr. John H. Joseph on Clinical Trials for Injectables
https://practicaldermatology.com/error/404/John H. Joseph, MD, joins Joel Cohen, MD, to discuss his work on clinical trials for neuromodulators and filler products at Music City SCALE.SCALE 2024: Dr. Michelle Henry on Innovative Skincare Products and Lasers in Skin of Color
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-michelle-henry-innovative-skincare-products-and-lasers-skin-color/26374/Michelle Henry, MD, discusses innovative skincare products and lasers in skin of color, including her top 10 tips for ensuring best outcomes and reducing adverse events, at Music City SCALE.Noah Worcester 2024: Dr. Brodell on Microscopes
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-brodell-microscopes/24579/Robert Brodell, MD, summarizes his lecture on Santa Cruz Antique Microscope Collection at the 2024 Noah Worcester Dermatological Society meeting.DermWireTV: Atopic Dermatitis Guidelines, Derm Devices, and New Research
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-atopic-dermatitis-guidelines-derm-devices-and-new-research/20234/In this episode of DermWire TV, we report on the new atopic dermatitis guidelines, the long-term safety of upadacitinib, and novel energy-based dermatology devices. From the new at-home treatment for molluscum contagiosum to the discovery of genetic factors in early-onset Merkel cell carcinoma, thisFDA Approves Roflumilast for Seborrheic Dermatitis in Young Patients
https://practicaldermatology.com/topics/other-dermatitis/fda-approves-roflumilast-for-seborrheic-dermatitis-in-young-patients/20230/Patrick Burnett, MD, PhD, chief medical officer of Arcutis Biotherapeutics, talks with Practical Dermatology® about the first new treatment for seborrheic dermatitis in more than 20 years, their newly approved ZORYVE (roflumilast)Topical Foam, 0.3% for use in patients aged 9 years or older.